Nov 01, 2022 8:01 am EDT CymaBay Announces Appointment of Charles McWherter, Ph.D. to Chief Scientific Officer and President of Research and Development
Oct 03, 2022 8:00 am EDT CymaBay Therapeutics Announces Three Presentations at The Liver Meeting® 2022
Sep 06, 2022 8:02 am EDT CymaBay Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 24, 2022 8:00 am EDT CymaBay Therapeutics to Participate in B. Riley’s Mini PBC Symposium on August 24, 2022
Aug 11, 2022 4:05 pm EDT CymaBay Reports Second Quarter and Six Months Ended June 30, 2022 Financial Results and Provides Corporate Update
Aug 04, 2022 4:05 pm EDT CymaBay Therapeutics to Report Second Quarter of 2022 Financial Results on Thursday, August 11, 2022
Aug 01, 2022 8:00 am EDT CymaBay Completes Enrollment for the RESPONSE Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis
Jun 22, 2022 8:00 am EDT CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
Jun 08, 2022 8:00 am EDT CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022